ReviewFrontiers in neuroscience2025
The interaction of regulated forms of cell death in the pathogenesis of severe facial paralysis and potential therapeutic strategies.
Review in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuronal cell death plays a central role in the pathogenesis of facial paralysis. In the constructed severe facial paralysis model, axonal damage becomes the key factor triggering retrograde neuronal degeneration, resulting in a large number of neuronal deaths, which seriously affects the function of the facial nerve. The basic fibroblast growth factor exhibits strong neuroprotective ability and can significantly reduce the neuronal mortality rate, providing a strong guarantee for neuronal survival. Viral infection is also an important pathogenic factor that cannot be ignored. Viruses such as herpes simplex virus type 1 can trigger neuroinflammation through the immune response, further exacerbating nerve damage. However, recent studies have also brought hope. Neural reconstruction techniques, targeted drugs, and stem cell therapies hold potential value in promoting the recovery of damaged neural functions. These research results reveal that multiple factors affect the survival and function of neurons in facial paralysis through different pathways, laying a theoretical foundation for targeted treatment against neuronal death. In the future, based on these mechanisms, developing new therapies will bring new treatment opportunities for patients with severe facial paralysis, potentially improving their prognosis and significantly enhancing their quality of life, with important clinical value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.